Piscitelli, Stephen C.

The effect of garlic supplements on the pharmacokinetics of saquinavir

Piscitelli, S. C., Burstein, A. H., Welden, N., Gallicano, K. D., & Falloon, J. (2002) · Clinical Infectious Diseases

HIV/AIDS drug development and treatmentPharmacogenetics and Drug Metabolism

Cited by 431

Clinical pharmacology of systemic antifungal agents: A comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development

Groll, A. H., Piscitelli, S. C., & Walsh, T. J. (1998) · Advances in pharmacology

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 377

Formulation and pharmacology of long-acting cabotegravir

Trezza, C., Ford, S. L., Spreen, W., Pan, R., & Piscitelli, S. (2015) · Current Opinion in HIV and AIDS

HIV/AIDS drug development and treatmentHIV/AIDS Research and Interventions

Cited by 179

Safety, Pharmacokinetics, and Pharmacodynamics of Cyclodextrin Itraconazole in Pediatric Patients with Oropharyngeal Candidiasis

Groll, A. H., Wood, L., Roden, M., Mickiene, D., Chiou, C. C., Townley, E., Dad, L., Piscitelli, S. C., & Walsh, T. J. (2002) · Antimicrobial Agents and Chemotherapy

Antifungal resistance and susceptibilityPharmaceutical studies and practices

Cited by 123

Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis

Walsh, T. J., Whitcomb, P., Piscitelli, S., Figg, W. D., Hill, S., Chanock, S. J., Jarosinski, P., Gupta, R., & Pizzo, P. A. (1997) · Antimicrobial Agents and Chemotherapy

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 109

Lack of Pharmacokinetic Interaction between Rilpivirine and Integrase Inhibitors Dolutegravir and GSK1265744

Ford, S. L., Gould, E., Chen, S., Margolis, D., Spreen, W., Crauwels, H., & Piscitelli, S. (2013) · Antimicrobial Agents and Chemotherapy

HIV/AIDS drug development and treatmentHIV/AIDS Research and Interventions

Cited by 83

A Phase 1b, Randomized, Single-Center Trial of Topical Cerdulatinib (DMVT-502) in Patients with Mild-to-Moderate Atopic Dermatitis

Piscitelli, S. C., Pavel, A. B., McHale, K., Jett, J. E., Collins, J., Gillmor, D., Tabolt, G., Li, R., Song, T., Zhang, N., et al. (2021) · Journal of Investigative Dermatology

Dermatology and Skin DiseasesPsoriasis: Treatment and Pathogenesis

Cited by 30